Nutex Health (NUTX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 26% year-over-year to $78.8 million, driven by new hospital openings, higher patient visits, and improved rates from the IDR process.

• Net loss widened to $8.8 million in Q3 2024, mainly due to $6.7 million non-cash warrant liability loss, $2 million stock-based compensation, and higher interest expense.

• Adjusted EBITDA surged to $13.5 million in Q3 2024 from $1.3 million a year ago, a 938% increase, reflecting operational improvements.

• Cash from operating activities rose to $23.1 million in Q3 2024 from $3 million in Q3 2023.

• Two reverse stock splits (1:15 in April and 1:10 in July 2024) were completed to regain Nasdaq compliance.

Financial highlights

• Gross profit margin improved to 27.8% in Q3 2024 from 11.3% in Q3 2023, with gross profit up 209% to $21.9 million.

• Operating income reached $9.7 million in Q3 2024, up from a loss of $821,000 in Q3 2023.

• For the first nine months of 2024, revenue grew 25% to $222.3 million, with mature hospitals up 13.5%.

• Adjusted EBITDA for the first nine months was $30.1 million, up 290% year-over-year.

• Cash and equivalents at September 2024 were $46.9 million, up 113% from year-end 2023.

Outlook and guidance

• Expecting higher patient volumes in Q4 due to seasonal trends, with two new hospitals opening in November and December.

• Four hospital openings planned for 2025, with one in early 2025 and three later in the year.

• Management expects continued growth in hospital visits and revenue per visit, supported by new facilities and improved IDR collections.

• Sufficient liquidity is expected for at least the next twelve months, with plans for further expansion and potential financing.

• Anticipates 60-70% of claims to be submitted through the IDR process by year-end, with ongoing administrative delays.